Drug Discovery World

AUGUST 31, 2022

The study authors suggest that antigen levels could help determine those patients most likely to benefit from therapies directed at fighting the virus. . Analysis of Covid patient blood samples. High blood antigen levels also correlated with some known risk factors for worse illness, such as being male.

Hospitals 130

Hospitals Trials Virus International 130

The Pharma Data

DECEMBER 29, 2020

29, 2020 /PRNewswire/ — Phase 3 program in hospitalized patients to continue based on passing futility analysis on ability to reduce incidence of death or mechanical ventilation. As in earlier outpatient trial, immune status when patients entered the trial was a strong predictor of viral load and clinical outcomes.

Hospitals 52

Hospitals Trials Clinical Trials Production 52

Drug Discovery World

SEPTEMBER 13, 2023

The authors conclude that this now well-defined subgroup of “inflammatory psychoses” calls for the development of a differential therapeutic approach in psychoses and, more specifically, the identification and development of further HERV-related precision medicine therapies. times more than the control group.

Protein Expression 130

Protein Expression Clinical Trials Hospitals Trials 130

Drug Discovery World

FEBRUARY 5, 2024

Science and technology innovator Danaher launched a strategic collaboration with Cincinnati Children’s Hospital Medical Center, with the goal of improving patient safety by addressing a leading cause of failure in clinical trials.

Small Molecule 162

Small Molecule Assay Development Production Science 162

Drug Discovery World

JULY 3, 2023

Dr Agapitos Patakas, CSO, Research & Development, Antibody Analytics, presented in this track on a customisable cell line platform for in vitro assessment of safety and efficacy of immune cell-directed therapies. This included broad antigen recognition, multivalent responses and the lack of MHC restrictions.

Engineering 130

Engineering Virus Therapies Treatment 130

The Pharma Data

JANUARY 20, 2021

Trial designed to investigate the cardioprotective properties of CardiolRx(TM) in patients hospitalized with COVID-19 who have a prior history of, or risk factors for, cardiovascular disease. The DSMC comprises independent experts who will assess the patient safety data, and, if needed, critical efficacy endpoints of the trial.

Hospitals 52

Hospitals Trials International Clinical Trials 52

The Pharma Data

JANUARY 27, 2021

COVID-19 Antibody Treatments Exceed Expectations in Early Trials. 27, 2021 — Promising new data on two antibody cocktails suggest these therapies can keep COVID-19 patients out of the hospital and even prevent illness altogether in some people. All tested negative for the virus but live with someone who has COVID-19.

Treatment 52

Treatment Trials Hospitals Virus 52

The Pharma Data

JANUARY 17, 2021

The treatment could be administered in primary care centers to people who test positive for COVID-19, avoiding hospitalization due to the progression of the disease and complementing the vaccine in the early phase after vaccination. BARCELONA, Spain , Jan. 18, 2021 /PRNewswire/ — Grifols (MCE: GRF, MCE: GRF.P,

Clinical Trials 52

Clinical Trials Treatment Trials Hospitals 52

Drug Discovery World

APRIL 20, 2023

To date, it seems that the likely mechanism of post- Covid-19 cognitive impairment is neuroinflammation triggered by the peripheral / systemic inflammation caused by the virus. New therapeutics of course depend on an understanding of biological mechanisms. Luckily, some clear findings are starting to emerge.

Drug Development 246

Drug Development Clinical Trials Drugs Virus 246

The Pharma Data

DECEMBER 17, 2020

(NASDAQ: REGN ) today announced that the New England Journal of Medicine (NEJM) has published initial clinical data from an ongoing seamless Phase 1/2/3 trial of the antibody cocktail casirivimab and imdevimab in non-hospitalized patients with COVID-19. “The investigational cocktail is now available to indicated high-risk U.S.

Hospitals 52

Hospitals Production Clinical Trials Virus 52

The Pharma Data

OCTOBER 28, 2020

Today’s data, involving an additional 524 patients from the ongoing Phase 2/3 trial, provides definitive final virology results and meets the clinical endpoint of reducing medical visits. In the overall patient group with detectable virus at baseline, the average daily reduction in viral load through day 7 was a 0.36

Virus 40

Virus Trials Clinical Trials Production 40

The Pharma Data

AUGUST 7, 2020

As the pharma industry stands firm in its commitment to advance the sector to fight Covid-19, news has emerged from the European Commission who intend to streamline the development of therapies using genetically modified organisms to treat Covid-19. Regenerative medicine and advanced therapies thriving despite Covid-19 disruption.

Clinical Trials 52

Clinical Trials Trials Packaging Therapies 52

The Pharma Data

APRIL 3, 2021

The CoVIg-19 Plasma Alliance today announced that the Phase 3 Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC) clinical trial sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), did not meet its endpoints. About the ITAC Trial.

Clinical Trials 52

Clinical Trials Trials Hospitals Treatment 52

The Pharma Data

OCTOBER 19, 2020

Synairgen’s study will evaluate the ability of SNG001, an inhaled formulation of IFN-beta-1a, to accelerate recovery among hospitalized patients receiving oxygen. The randomized, double-blind, placebo-controlled trial is expected to enroll 900 patients across approximately 20 countries. BOSTON and DURHAM, N.C.,

Trials 40

Trials Hospitals Therapies Clinical Trials 40

Drug Discovery World

NOVEMBER 1, 2022

Ground-breaking therapies . In September this year, Aucentra Therapeutics announced that it received regulatory approval to progress to a Phase I/II trial for Auceliciclib in combination with Temozolomide for recurrent/refractory Glioblastoma multiforme (GBM) patients 3. . million from the Medical Research Future Fund.

Drugs 130

Drugs Science Therapies Clinical Trials 130

NIH Director's Blog: Drug Development

FEBRUARY 16, 2021

hospitals are stretched to the limit trying to help people battling serious cases of COVID-19. This improvement stems from several factors, including the FDA’s emergency use authorization (EUA) of a number of therapies found to be safe and effective for COVID-19. Credit: NIH Right now, many U.S.

Clinical Trials 52

Clinical Trials Hospitals Vaccine Trials 52

Codon

JANUARY 21, 2024

Human challenge trials were an indispensable part of the development of the malaria vaccine, R21/Matrix-M, endorsed by the World Health Organization last October. But for all of their benefits, human challenge trials have their drawbacks. Jake himself has participated in both Zika and Shigella challenge trials.

Vaccine 111

Vaccine Trials Disease Virus 111

The Pharma Data

MAY 4, 2021

INDIANAPOLIS , May 4, 2021 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) is donating COVID-19 therapies to Direct Relief, enabling the humanitarian organization to provide COVID-19 therapies at no cost to low- and lower-middle-income countries most heavily impacted by the pandemic.

Therapies 52

Therapies Hospitals FDA Approval Long-Term Care Facilities 52

The Pharma Data

JANUARY 12, 2021

Doses are being supplied for use pursuant to the FDA Emergency Use Authorization for high-risk patients with mild to moderate COVID-19 in order to reduce the risk of progression to severe COVID-19 and/or hospitalization. To date, nearly 15,000 people have participated in casirivimab and imdevimab clinical trials. Yancopoulos , M.D.,

Government 52

Government Hospitals Virus Production 52

The Pharma Data

MARCH 14, 2023

Based on our clinical trial results, we are hopeful that QDENGA could have a positive impact on the incidence of symptomatic dengue in Brazil, including dengue cases that require hospitalization. The TIDES trial met its primary endpoint of overall vaccine efficacy (VE) by preventing 80.2% 2 In 2022 Brazil saw more than 1.4

Vaccine 40

Vaccine Virus Hospitals Trials 40

NIH Director's Blog: Drug Development

FEBRUARY 1, 2022

The NIH continues to support the development of some very innovative therapies to control SARS-CoV-2, the coronavirus that causes COVID-19. Though more study is needed, the researchers say the decoy therapy could potentially be delivered directly to the lungs through an inhaler and used alone or in combination with other COVID-19 treatments.

Virus 52

Virus Clinical Trials Engineering Immune Response 52

The Pharma Data

AUGUST 12, 2020

New research has warned that minority groups and people of colour are underrepresented in current trials for COVID-19 therapies, despite the disproportionately higher rates of infection, hospitalisation and death faced by these groups.

Research 52

Research Clinical Trials Pharmacy Trials 52

The Pharma Data

AUGUST 6, 2020

The Imperial College London researchers who led the study – involving 19 different hospitals across Europe, including Hammersmith Hospital in London – say they now want to find out why. More than 400 had other underlying conditions: 53% were receiving therapy, of whom a quarter were having chemotherapy.

Virus 52

Virus Hospitals Treatment Clinical Trials 52

The Pharma Data

NOVEMBER 22, 2020

As the Pfizer and BioNTech COVID-19 vaccine goes to regulators and the Moderna vaccine approaches the end of its Phase III trials, AstraZeneca and the University of Oxford announced high-level results from an interim analysis of their COVID-19 vaccine, AZD1222. Trials are also being run in the U.S.,

Vaccine 52

Vaccine Virus Trials Regulations 52

The Pharma Data

AUGUST 30, 2021

Pulmonary infection with the SARS-CoV2 virus can progress to acute respiratory distress syndrome (ARDS), in which inflammation and neutrophil hyperactivation play a central role. There is currently a lack of therapies for ARDS associated with COVID-19.

Clinical Trials 52

Clinical Trials Drugs Trials Hospitals 52

PerkinElmer

FEBRUARY 28, 2022

Fast-forward to today, and thousands of scientists have turned their attention to studying SARS-CoV-2, the virus responsible for the current COVID-19 pandemic. This research pivot led to a torrent of scientific papers describing the structure and biology of the virus being published. μl of ATPlite-substrate per well.

Virus 52

Virus Vaccine Clinical Trials Hospitals 52

The Pharma Data

JANUARY 25, 2021

With a mandate to serve patients and an emphasis on public health, CSL Behring is a co-founder of the CoVIg-19 Plasma Alliance , which aims to develop an anti-coronavirus hyperimmune globulin (H-Ig) made from a convalescent plasma for the treatment of hospitalized adults at risk for serious complications of COVID-19. “It

Vaccine 52

Vaccine Therapies Virus Trials 52

The Pharma Data

MARCH 22, 2021

Companion dose-ranging phase II trial showed significant and comparable viral reductions for a range of doses of casirivimab and imdevimab. Casirivimab and imdevimab also met all key secondary endpoints in the phase III REGN-COV 2067 trial, including the ability to reduce symptom duration from 14 to 10 days (median numbers).

Virus 52

Virus Clinical Trials Trials FDA 52

The Pharma Data

MAY 4, 2021

An initial donation of 400,000 baricitinib tablets is being made immediately available to the Indian government for eligible hospitalized COVID-19 patients in India and Lilly will work urgently to increase the quantity of donated product multifold over the coming weeks. Ricks , Lilly chairman and CEO.

Licensing 40

Licensing Licensing Therapies Laboratories 40

Drug Discovery World

SEPTEMBER 16, 2022

Here, DDW Editor Reece Armstrong explores the global hubs of innovation for cell and gene therapies. Since the approval of Kymirah in 2017, the cell and gene therapy sector has emerged as an exciting and innovative market, representing some of the most promising drugs the pharmaceutical industry has ever seen. .

Therapies 130

Therapies Clinical Trials Production Trials 130

The Pharma Data

OCTOBER 22, 2020

Food and Drug Administration (FDA) has approved the antiviral drug Veklury (remdesivir) for the treatment of patients with COVID-19 requiring hospitalization. As an antiviral drug, Veklury works to stop replication of SARS-CoV-2, the virus that causes COVID-19. to 1.52).

FDA Approval 52

FDA Approval Treatment FDA Hospitals 52

The Pharma Data

APRIL 14, 2021

government for its neutralizing antibody therapies authorized for emergency use as a treatment for COVID-19. Bamlanivimab and etesevimab together and bamlanivimab alone are not authorized for use in patients: who are hospitalized due to COVID-19, OR. who require oxygen therapy due to COVID-19, OR. Limitations of Authorized Use.

Government 52

Government Long-Term Care Facilities Hospitals Treatment 52

The Pharma Data

NOVEMBER 23, 2020

Studies funded by a number of grants in the beginning of May are already providing insight into why the virus seems to affect the cardiac system, Lloyd-Jones said. ” COVID-19 was also a major focus of this year’s meeting. . Also, much of the microthrombi occurring in these patients appears to be a direct result of the infection.

Research 52

Research Virus Therapies Trials 52

The Pharma Data

OCTOBER 19, 2020

The assay targets on coronavirus-specific nanobodies and tests affinity and efficacy to prevent the virus infection. . Testing Therapies, Antivirals and Vaccines. There has been some discussion of running challenge trials for COVID-19 vaccines. There has been some discussion of running challenge trials for COVID-19 vaccines.

Vaccine 52

Vaccine Virus FDA Clinical Trials 52

Creative Biolabs

SEPTEMBER 6, 2022

Researchers at Cincinnati Children’s Hospital Medical Center published a research paper in Nature titled: Pregnancy enables antibody protection against intracellular infection. In addition, many more monoclonal antibodies are in clinical trials, some of which have not shown strong therapeutic effects. Reference Erickson, J.J.,

Vaccine 52

Vaccine Virus Clinical Trials Disease 52

The Pharma Data

OCTOBER 27, 2021

. “The main finding in our study is that the equine hyperimmune globulins antibodies developed against the spike protein of the ancestral SARS-CoV-2 had high neutralizing action against the new variants of the virus, such as the gamma strain. The next step of the research is to conduct a phase 1/2 clinical trial in humans.

Clinical Trials 52

Clinical Trials Virus Production Trials 52

The Pharma Data

OCTOBER 14, 2020

Food and Drug Administration (FDA) to begin a Phase I clinical trial of hAd5-COVID-19, the company’s novel COVID-19 vaccine candidate that targets both the inner nucleocapsid (N), engineered to activate T cells, and outer spike (S) protein, engineered to activate antibodies against the coronavirus (SARS-CoV-2). i,ii,iii,iv.

Vaccine 52

Vaccine Trials FDA Clinical Trials 52